A clinical study of CB-708, an orally administered small molecule inhibitor of CD73
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2019
At a glance
- Drugs CB 708 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 07 Jan 2019 According to a Calithera Biosciences media release, the company expects acceptance of IND application and initiation of the study in 2H 2019.
- 20 Aug 2018 New trial record
- 07 Aug 2018 According to a Calithera Biosciences media release, the company is expected to file an IND for CB-708 and to start this study in 2019.